Present and Future of Personalised Medicine for Endocrine Cancers

Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients...

Descripción completa

Detalles Bibliográficos
Otros Autores:	Ronchi, Cristina L. (Editor), Altieri, Barbara (Otro)
Formato:	Libro electrónico
Idioma:	Inglés
Publicado:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Materias:	Medicine papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing's disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters
Ver en Biblioteca Universitat Ramon Llull:	https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009666914906719